 |
| from ryangruss.com |
Public Interest Note:
We hardly need to read or watch the news everyday to observe one of the fastest growing trends in America: obesity. Obesity is defined by the Center for Disease Control and Prevention “as a body mass index (BMI) of 30 or greater. BMI is calculated from a person’s weight and height and provides a reasonable indicator of body fatness” According the CDC, nearly every state in the U.S. has populations containing at least 20% obese adults1. Of course, obesity does not merely affect Americans, as the World Health Organization estimates more than 300 million people around the world are obese2.
Our friends and family and self-help books tell us that “beauty comes in all shapes and sizes” and we want to believe this. Hearing this makes us feel beautiful no matter what we look like, and we’re lucky to be surrounded by people that will love us unconditionally. But at the same time it’s important to realize that it may not be so beautiful to be dependent on insulin injections to survive, suffering from chronic inflammation and increased susceptibility to infections. The link between obesity and a variety of health concerns including heart disease and diabetes is well established. A 2010 study spearheaded by Kaiser Permanente and published in the New England Journal of Medicine (NEJM) showed that heart disease has dropped significantly-by 24%- between 1999-2008. Much of this decline, the research team noted, is attributable to decreases in cigarette smoking and increases in the use of cardio-protective medications during the course of those years3. Importantly, in the same issue of NEJM a perspective editorial by Drs. Jerimiah Brown and Gerald O’Conner, noted that during those same years 1999-2008, the incidence rate for Type 2 Diabetes and obesity increased. They concluded “These trends suggest that we are succeeding some areas by reducing the burden of modifiable risk factors, such as smoking, hypertension, and high cholesterol levels, but that our society’s diabetes and obesity problems are worsening.”4 The data supporting a link between obesity and diabetes is clear, both of which cause detriment not only to us individuals, but also to our community with increased medical costs, unhealthy workforces and reduced life expectancies.
The role of scientists and doctors is vital and necessary in fighting this disappointing epidemic. In the early 1950’s Dr. Hans Kraus had published a series of provoking research articles regarding the lack of physical activity of Americans, specifically the children. In comparison to European children in a series of physical activity tests, Kraus and colleagues revealed out of 4,400 students (age 6-16) “56 percent of the U.S. students failed at least one of the test components…only about 8% of the European children failed”5. These startling data quickly stirred interest among the general public, as people began to consider more the importance of diet and exercise to lead healthy, productive lives. Not only the lives of individuals, but the life of the country as a whole and in 1955 President Eisenhower invited Dr. Kraus for a meeting to establish a course of action based on the data presented. In less than year, the President commissioned the “President’s Council on Youth Fitness” to organize a new initiative called the “Presidential Fitness Awards” in which for school children complete a series of physical fitness tests to receive one of these awards. The program functions still today as a way to fight obesity and helped bolster the “Let’sMove” campaign commissioned by First Lady Michelle Obama as a way to “change the way a generation of kids thinks about food and nutrition” and reduce childhood obesity to 5% by 2030 6. The achievement lead by Kraus over 50 years ago highlights the value of cross talk between scientists and the public and set into motion America’s growing interest in fitness and healthy lifestyles.
Type 2 Diabetes: The Immunology Behind the Disease
Eating whole foods, balanced meals and small portions play a role in maintaining our figures curvy and toned, while simultaneously regulating body’s ability to function properly. Our bodies need to consume foods for nutritional benefit, but what happens when we eat too much, especially foods high in salt, sugar and fat? The most witnessed observation is the accumulation of weight, in the form of fat, deposits in our bellies contributing to our subcutaneous (just beneath the skin) or visceral (covering our organs) fat tissue. When we think of fat, most of us think of glossy white lining of our T-bone steaks. Although it looks like it serves no better function that to moisten our steaks, our fat tissue is a quite dynamic place to be, especially for an adipocyte. Adipocytes are the cells that largely make up our fat tissue (anatomically referred to as adipose tissue). These cells are unique compared to all the other cells in our bodies. Adipocytes store fats derived from food and liver metabolism. The storage of fats by these cells are vitally important such that adipose tissue protects our organs and acts as a buffer to help ward off certain pathogens. Moreover, because the metabolism of fat releases more energy than proteins or carbohydrates, adipose tissue represents the largest energy storage in our bodies. When we eat too much and exercise too little, our adipose tissue increases, literally. As our adipocytes store more and more fat they swell to accommodate the new intake. This of course can be very bad for the rest of our body-most obviously for the organs that lie beneath this mounting fat-which often times is why obesity is linked to a variety of progressive diseases, simply because our diagnostic tools cannot access the affected organ and therefore inhibit many useful prevention strategies to combat such diseases.
So what does any of this have to with your immune system? As I hope you will begin to appreciate, your immune system is an amazing, peculiar system that seems to be involved in nearly every function in your body. Least of which includes your fat-or at least how it’s maintained. It’s incredible that our bodies have evolved to become vastly dependent upon one, single protein, insulin, with which we wouldn’t be able to focus, our blood pressure would raise uncontrollably-it short, and our body would crash. Insulin is a natural hormone produced by beta islet cells in the pancreas in response to increased blood glucose levels. The insulin secreted by the pancreas signals through insulin receptors, which are expressed by the cells that regulate our blood glucose levels, largely our liver cells and adipocytes. Once insulin has bound to its receptor it activates the adipocytes to absorb any glucose that comes its way, thereby lowering the blood glucose levels and returning the body to homeostasis. When the body is unable to produce insulin or becomes unable to respond to insulin-diabetes develops.
Let’s be clear about one thing: your immune system is tightly involved in the development of Diabetes-both Type 1 and Type 2, but in completely different ways. Type 1 Diabetes (also known as juvenile diabetes and diabetes mellitus) is an autoimmune disorder. Recall from the last post that autoimmunity is the result of self-reactive T cells circulating through the body, recognize self-antigen as foreign and trigger the death of any cell expressing that particular antigen. In the case of Type 1 Diabetes, the self-antigen that’s being attacked is insulin-so therefore beta islet cells are under attack by the body’s own immune system. It is for this reason that people diagnosed with this type of diabetes must take insulin shots to balance their blood-glucose levels since they cannot produce insulin independently. Conversely, Type 2 Diabetes (T2D) is a metabolic disorder tightly associated with obesity and results in insulin insensitivity that is, although the body can make insulin just fine, the adipocytes can’t respond to it and therefore can’t remove lower glucose levels from the blood. Essentially, the body is consuming more sugar and fat than it can regulate, and for reasons incompletely understood, the body loses the ability to recognize all the insulin being produced because of this resulting in hyperglycemia. The role of the immune system is quite evident in the case of Type 1 Diabetes, but it less obvious in the pathology of T2D.
In the 1990’s it was demonstrated that obese tissue released more inflammatory cytokines than lean tissue, thus beginning the investigation of the role inflammation in T2D development 7. Cytokines are small molecules secreted by immune cells that activate the immune system, some cytokines promote inflammation. Two of the most studied inflammatory cytokines are TNFalpha and IL-1beta, which are usually released during infections. These cytokines are secreted by immune cells once the cell receives instructions to do so. Immune cells are able to recognize invading pathogens quickly by recognizing certain pathogen-associated molecular patterns (PAMPs), which are only present on microbes and not our own cells. PAMPs stimulate Toll-like receptors (TLRs) and NOD-like receptors (NLRs) to induce TNFalpha and IL-1beta release, respectfully. These cytokines are inflammatory because they recruit more immune cells to the site of infection and starts the process of inflammation characterized by swelling, fever, redness, and pain-all of which is required to fight infection. This clever detection system allows for the quick response by innate immune cells (macrophages, dendritic cells, and neutrophils) to activate the rest of the immune system to destroy the invading bug. Our innate immune cells are the first the cells to respond to an immunological threat.
Within the past couple decades it was discovered that fat tissue does not merely contain adipocytes, but is full of immune cells too, especially one particular immune cell-the macrophage. The macrophage is named so because it is one of the largest immune cells and engulfs nearly everything it crosses. You can think of it as the janitorial cell of the body, clearing tissue from cell debris and microbes. Earlier just this year, Vishwa Deep Dixit’s laboratory based at Louisiana State University, established a role for fat-associated macrophages in controlling obesity-induced T2D. They had established a model to study T2D by engineering mice that were deficient for a particular NLR (NLRP3), which is important for IL-1beta release. When these mice were fed a high-fat diet, their blood-glucose levels were lower than their wild-type counterparts. Furthermore, the fat-associated macrophages possessed anti-inflammatory characteristics whereas wild-type mice fed a high-fat diet contained highly inflammatory macrophages within their fat tissue. Moreover, they showed that IL-1beta released by macrophages induce other immune cells to develop insulin resistance and perpetuate the inflammatory response, which ultimately leads to chronic inflammation and T2D 8. Although, these authors convincingly demonstrated the role of NLRP3-induced IL-1beta in the development of T2D and chronic inflammation, what was directly activating the fat-associated macrophage to produce IL-1beta in the first place remained elusive.
As you’ll recall, macrophages become activated via TLR or NLR stimulation. Macrophages usually require a TLR or NLR activator in order to produce inflammatory cytokines like IL-1beta. So, in the absence of microbial infection (which is the standard activator of these receptors) how do these inflammatory cytokines get released in the fat tissue? What is present in the adipose tissue that activates macrophages to release IL-1beta, a cytokine critically important in the progression of T2D? That is the great mystery and focus of the research discussed below that was recently published by Dr. Jenny Ting's research group at the University of North Carolina, Chapel Hill.
Treating Diabetes and Obesity: Why This Research Paper Matters:
The best prevention is clear: exercise daily and eat balanced, small-portioned meals. However, in some cases, people are more genetically susceptible in developing the disease or for some individuals, diet and exercise isn’t enough to control the disease. For these people, there is little treatment options available. Currently, anti-inflammatory diets are popping up on the scene as alternative diet plans to help combat diseases associated with chronic inflammation. Such diets are heavy in foods that people should be eating more of regardless of their health conditions: whole vegetables and fruits rich in vitamins and anti-oxidants, which help combat inflammation. Although the value of eating such foods is becoming increasingly acknowledged, the mechanisms by which these foods block inflammation is less known. For example, although for decades, millions of people take omega-3 fatty acid (fish oil) supplements for its anti-inflammatory properties, it was not until 2010 that a team of researchers identified the exactly how omgea-3 fatty acids were able to dampen inflammation! Not only did these researchers discover the receptor that binds omega-3 fatty acids and that this receptor inhibits TLR-induced pro-inflammatory cytokine release from macrophages, but they also provide incredible data showing that omega-3 fatty acids that bind this receptor promotes insulin sensitivity!9 This new data suggests the use of omega-3 fatty acid as a possible treatment option specifically for T2D. As it turns out, many drugs and supplements are prescribed without the knowledge of how the drug actually works. There is no doubt that more effective drugs could be available if we better understood the underlying mechanisms behind disease.
As a testament for the work done in mice regarding the role of IL-1beta in T2D pathogenesis, recent clinical trials are underway testing a molecule that blocks IL-1beta signaling, anakinra. A 2007 NEJM paper discussing the results of one study using anakinra showed that it improved glucose levels and reduced system inflammation in patients receiving the drug 10. But again and importantly, this is clinical trials and the need to discover new drug targets and development of novel treatments for T2D is needed to help combat a disease that plagues millions of our parents, friends and increasingly-our children. Dr. Jenny Ting’s UNC research group recently published in Nature Immunology compelling data indicating how saturated fats activates a newly identified pathway involved in the development of T2D. With this latest discovery, it is likely that their data will bolster many promising new therapeutic targets to utilize in our fight against T2D.
What the &*%$#! Does the Title Mean?!
Haito Wen, et al. “Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling”. Nature Immunology. 12(5):408-415. (2011).
 |
| Diagram illustrating NALP3 inflammasome complex. Although a number of stimuli was known to induce inflammation via NALP3 activation (abestos, cholesterol, silica, etc), prior to the research discussed here, fatty acids high in diabetes patients was not known to contribute to inflammation through the same mechanism! Image from www.invivogen.com |
2) ASC is a small intracellular protein that happens to also consist of pyrin domains allowing it to bind to NLRP3 very nicely. See, NLRP3 isn’t very useful on its own; it needs ASC to carry out a function. The value of ASC lies with what it brings to NLRP3: an enzyme. Specifically, an enzyme called caspase-1 associates with ASC, so when NLRP3 recruits ASC, it’s recruiting caspase-1 too. Caspase-1 is a very important enzyme for the immune response because it chops up big cytokines into a smaller, more functional fragment that can be secreted by the cell. What kind of cytokines does caspase-1 process? None other than the much-talked-about pro-inflammatory cytokine, IL-1beta.
3) Inflammasome is a term to describe a group of proteins interacting with each other that promote inflammation. The NLRP3-ASC inflammasome therefore refers to the complex containing NLRP3, ASC, and caspase-1. It is known that a wide variety of PAMPs and danger-associated signals activate the formation of this signaling complex. Recently, a lot of work has been done investigating the role of the NLRP3 inflammasome in a variety of infections and injuries. Collectively, it’s now known that the NLRP3 inflammsome is activated in response to stressful conditions (stressful to a cell, that is), like when neighboring cells are dying or during infection. It is important to recall, that in obesity these events are not happening in the adipose tissue, so what the stressful stimuli are is the point of this research paper.
4) Insulin signaling refers to what happens when insulin binds its specific receptor. Upon binding to insulin, the insulin receptor recruits another protein called the insulin receptor substrate, which will instruct the cell to survive and divide, to efficiently remove glucose from the blood. The concept with T2D progression is that too much glucose is around such that insulin is being produced by the pancreas all the time in high amounts-which desensitizes adipocytes, so that blood-glucose levels remain high. One likely candidate that causes this effect is impaired insulin receptor signaling.
Put all these terms together and we can now infer that: Certain fats we eat cause the NLRP3 inflammasome to assemble. The NLRP3 inflammasome contains caspase-1, which will process IL-1beta for release into tissue, which not only promotes inflammation but also blocks insulin receptor signaling, therefore instigating the onset of T2D.
Ready for an adventure? Read on for a guided-tour through the scientific data!
 |
| Palmitate is an example of a saturated fatty acid, common at high levels in obese and T2D patients. Image from www.yellowtang.org |
The first thing Wen and colleagues logically wanted to determine was whether palmitate could in fact activate the inflammasome, as their title suggests. To do this, they activated macrophages in culture with lipopolysaccharide (LPS), which is required to make what is called “pro-IL-1beta”-the protein that caspase-1 cleaves into mature IL-1b for secretion. If you want to measure IL-1beta released by macrophages stimulated with only LPS, you will hardly find a trace of it. Wen, et al. show that LPS-primed macrophages will secrete loads of IL-1beta when there palmitate around in a time and dose-dependent manner. Furthermore, palmitate only signals IL-1beta release from macrophages that express NLRP3 and ASC as macrophages deficient in either of these proteins significantly reduce the amount of IL-1beta produced. These cytokine effects appear to be NLRP3 inflammasome-specific since when they look at another cytokine (TNFalpha or IL-6), which don’t need caspase-1, palmitate does not affect their secretion. Finally, the authors illustrate, biochemically, that palmitate activates caspase-1 allowing the cleavage of pro-IL-1beta into mature IL-1beta. The data is clear: high levels of the saturated fat, palmitate, promotes the release of the pro-inflammatory cytokine IL-1beta via NLRP3-inflammasome dependent mechanism. Amazingly, these effects don’t occur when LPS-primed macrophages are stimulated by unsaturated fatty acids. But how is this happening? Is the saturated fatty acid activating the inflammasome directly or indirectly?
As mentioned, when cells are stressed out they signal the NLRP3 inflammasome to assemble and start to secrete inflammatory cytokines to warn the rest of the immune system that something isn’t right and that help is needed. It is well established when cells are stressed, their mitochondria (the energy machine of the cell) loses membrane potential and reactive oxygen species (ROS) start to seep into the cytosol. Furthermore, it’s also known that ROS controls NLRP3 association with ASC and is therefore crucial in inflammasome assembly.
So it makes perfect sense for the authors to investigate whether palmitate can activate ROS. Using a special dye that turns fluorescent in the presence of ROS, Wen, et al. show that palmitate increases ROS generation in cells and that this effect is blocked in the presence of a ROS-inhibitor. Moreover in the presence of palmitate, they showed that IL-1beta is produced, but now-in the presence of this ROS-inhibitor, caspase-1 activity and IL-1beta production greatly diminishes. All together, these data signify a novel finding-and the basis of how this story ended up in Nature Immunology: palmitate, a fatty acid associated with obesity, causes high levels of IL-1beta production from macrophages by stressing cells to produce ROS and activate the inflammasome. But we have only reached the tip of this iceberg, and many more questions must still be answered to complete this story. One of which is: how do saturated fats stress out cells?
The authors explain that “the AMP-activated protein kinase (AMPK) has emerged as an essential mediator of fatty acid metabolism and it suppresses ROS production” and its activity promotes the development of anti-inflammatory macrophages. The researchers then set out to test their hypothesis that “AMPK plays a role during inflammasome activation by palmitate”. Again, using that ROS-sensitive fluorescent dye, they provide data indicating that activation of AMPK inhibits palmitate-induced ROS production and IL-1beta release. Interestingly, palmitate appears to deactivate AMPK, so that ROS can accumulate in the cell and promote NLRP3 inflammasome assembly and activity.
These data suggest that AMPK activation plays a large role in directing inflammasome activation and that AMPK activity can be exploited by external stimuli like palmitate to promote inflammation. Importantly, this exploitation of AMPK appears to be specific to palmitate and not PAMPs or danger signals associated with injury and infection. This is an important distinction because they way these danger signals induce ROS production is by creating pores in the membrane and opening ion channels. But none of these stresses were induced by palmitate, which begged the question: we now have data that palmitate inhibits an enzyme that blocks ROS, which in effect allows ROS to accumulate in the cell, but how in the world was ROS being generated in the first place by palmitate?
The answer appears to lie in process called autophagy, which cells utilize to get rid of old organelles and metabolites for energy. It’s a highly evolutionarily conserved process that is vital in cell survival. More recently, it’s been shown that AMPK positively regulates autophagy during fatty acid metabolism. In the process of metabolizing fatty acids (aka autophagy) a little bit of ROS is generated. Wen, et al. continue to show a number experiments to demonstrate that palmitate deregulates autophagy by inhibiting AMPK. So not only are macrophages highly inflammatory in the presence of unsaturated fatty acids, but their autophagasomal machinery is messed up, which just further perpetuates inflammasome activation. In short, a single stimulus, palmitate can turn a usually anti-inflammatory macrophage (expressing AMPK) to a potent pro-inflammatory macrophage. This would be great news if the plan was to fight a bacterial infection, where inflammatory macrophages are needed to destroy the pathogen, yet in T2D, there isn’t a pathogen and these patients have chronic inflammation, which as this new data suggests is likely due to the high saturated fat diet consumed. Things couldn’t get possibly worse, right?
Of course they can, especially with T2D since we know the disease isn’t solely an inflammatory condition, but also affects the body’s ability sense insulin. So what does all of this palmitate data have to do with that? Wen and colleagues proceed with a series of elegantly designed experiments to investigate the role of palmitate in insulin signaling. First, they show that liver cells pre-treated with IL-1beta are less sensitive to insulin that unprimed cells based on insulin receptor activity. Furthermore, they show this happens because IL-1beta blocks IRS-1 function, the protein responsible for promoting insulin sensitivity and cell survival. Even more compelling was the data in which they illustrate that if they gave media from palmitate-activated macrophages, which would contain IL-1beta, to liver cells, the same effect was observed.
They repeated this experiment with NLRP3 and caspase-1 deficient macrophages, which had no effect on insulin receptor activity suggesting that palmitate activates macrophages to release IL-1beta in a NLRP3 inflammasome-dependent manner, which can then go on to inhibit insulin signaling in liver cells. If you recall, interference of insulin signaling will have detrimental effects for liver and fat cells’ ability to remove glucose from the blood, thereby promoting the development of T2D.
To study this more closely, in regards to T2D, the authors fed mice a high fat diet for 12 weeks and show that compared to mice fed on a low-fat diet, had higher blood-glucose levels. Moreover, mice deficient in IL-1beta, ASC or NLRP3 had glucose levels similar to that of a wild-type mouse on a lean diet! Finally, their in vivo data corroborated their in vitro findings that inflammasome activation within macrophages blocks insulin receptor signaling. Collectively, Dr. Jenny Ting’s research group provided valuable insight how saturated fats control not only our weight, but also our immune system.
Not only did they provide correlative evidence about palmitate, but the also went the extra mile in terms of experimental proof to identify the mechanism by which palmitate contributes to T2D disease. This is why this particular research is regarded highly by the scientific community and published in high-profile journals. Not only did Wen, et al. convincingly show how palmitate increased IL-1beta production, but the also revealed a promising new set of targets for T2D and chronic inflammatory diseases: autophagy. This is very exciting research that is bound to play a significant role in supporting the development of future treatment options for the millions of people suffering from such ailments! However, as their last figure nicely demonstrates, remember that the best prevention to T2D-even if you’re genetically susceptible- it to maintain a low-fat diet and try to fit in a bit of exercise each day.
 |
| Wen, et al. contributed significant understanding to the inflammatory mechanism behind T2D showing that the fatty acid, palmitate activates the NALP3 inflammasome, enhancing inflammation in adipose tissue and inducing insulin resistance and beta-cell dysfunction. Image from discoverymedicine.com |
Oh, and one last thing to keep in mind: mice are quite active during the day, roaming around and playing with each other, so it’s likely that the effects shown in this research paper regarding mice kept on a high-fat diet could be greatly exacerbated if the mice were sedentary! On that note, I think I’ll go for a run after work today, maybe you’ll be inspired to do something active too!
Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, & Ting JP (2011). Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature immunology, 12 (5), 408-15 PMID: 21478880References and Further Reading:
1: Center for Disease Control and Prevention. “U.S. Obesity Trends: Trends by State 1985-2009”
2: WHO. “WHO Fact Files: Ten facts on obesity”. (2010).
3: Yeh, RW., et al. “Population trends in the incidence and outcomes of acute myocardial infarction”. NEJM. 362:2155-2165. (2010).
4: Brown, JR and O’Conner, GT. “Coronary heart disease and prevention in the United States”. NEJM. 362:2150-2153. (2010).
5:The President’s Council on Physical Fitness and Sports. “History of the President’s Council on Physical Fitness and Sports (1956-2006)”.
6: Let’s Move: America’s move to raise a healthier generation of kids. “White House task force on childhood obesity report to the president”. (2010).
7: Hotamisligil, GS, et al. “Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance”. Journal of Clinical Investigation. 95:2409-2415. (1995).
8: Vandanmagsar, B., et al. “The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance”. Nature Medicine. 17(2): 179-188. (2011).
9: Oh, DY, et al. “GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects”. Cell. 142(5):687-698. (2010).
10:Larsen, CM, et al. “Interleukin-1-receptor antagonist in type 2 diabetes mellitus”. NEJM. 356: 1517-1526. (2007).
11: Boden, G., et al. “Interaction between free fatty acids and glucose metabolism”. Curr. Opin. Clin. Nutr. Metab. Care 5: 545-549. (2002).